Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1043 · 1 trial · 2 indications
To assess the safety and tolerability of a single or multiple doses of AZD1043 in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
| Arm | Type | Description |
|---|---|---|
| Part A1 (Global SAD): Cohort 1 - AZD1043 (Dose 1) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 1) or placebo. |
| Part A1 (Global SAD): Cohort 2 - AZD1043 (Dose 2) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 2) or placebo. |
| Part A1 (Global SAD): Cohort 3 - AZD1043 (Dose 3) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 3) or placebo. |
| Part A1 (Global SAD): Cohort 4 - AZD1043 (Dose 4) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 4) or placebo. |
| Part A1 (Global SAD): Cohort 5 - AZD1043 (Dose 5) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 5) or placebo. |
| Part A1 (Global SAD): Cohort 6 - AZD1043 (Dose 6) | EXPERIMENTAL | Participants will receive a single dose of AZD1043 (Dose 6) or placebo. |
| Part A2 (Japanese SAD): Cohort 1 - AZD1043 (Dose X) | EXPERIMENTAL | Japanese participants will receive a single dose of AZD1043 or placebo. |
| Part A2 (Japanese SAD): Cohort 2 - AZD1043 (Dose Y) | EXPERIMENTAL | Japanese participants will receive a single dose of AZD1043 or placebo. |
| Part A3 (Chinese SAD): Cohort 1 - AZD1043 (Dose Z) | EXPERIMENTAL | Chinese participants will receive a single dose of AZD1043 or placebo. |
| Part B1 (Global MAD): Cohort 1 - AZD1043 (Dose A) | EXPERIMENTAL | Participants will receive multiple doses of AZD1043 or placebo. |
| Part B1 (Global MAD): Cohort 2 - AZD1043 (Dose B) | EXPERIMENTAL | Participants will receive multiple doses of AZD1043 or placebo. |
| Part B1 (Global MAD): Cohort 3 - AZD1043 (Dose C) | EXPERIMENTAL | Participants will receive multiple doses of AZD1043 or placebo. |
| Part B2 (Japanese MAD): Cohort 1 - AZD1043 (Dose D) | EXPERIMENTAL | Japanese participants will receive multiple doses of AZD1043 or placebo. |
| Name | Type | Description |
|---|---|---|
| AZD1043 | DRUG | Single or multiple doses of AZD1043 will be administered. |
| Placebo | OTHER | Matching placebo to AZD1043 will be administered. |
Inclusion Criteria: * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. * Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oop...
Top 20 of 35 competitors
AZD1043 is an investigational small molecule being developed by AstraZeneca PLC for obesity. It is in Phase 1 clinical development and has not been approved by any regulatory agency. The program sits within AstraZeneca's metabolic therapeutic area and is currently being evaluated in a single recruiting study.
AZD1043 is being studied for obesity, including in adults living with overweight and/or obesity. It is an investigational therapy, so it is not yet available as a treatment outside of clinical trials. Its development focuses on the metabolic therapeutic area.
AZD1043 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating the compound in obesity. The drug remains investigational and is not commercially available.
AZD1043 is in Phase 1 clinical development. It has one active, recruiting trial and no completed trials. As a Phase 1 asset, it is investigational and has not received FDA approval. The program is being run in adults with overweight and/or obesity.
AZD1043 is being evaluated in the Phase 1 trial NCT07511205, titled a study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of AZD1043 in healthy adult participants living with overweight and/or obesity. The trial is recruiting, is randomized, double-blind, and controlled, with planned enrollment of 104 participants across the United States and United Kingdom.
AZD1043 is a small molecule, but its specific molecular target has not been disclosed. It is being developed for obesity within AstraZeneca's metabolic portfolio. The Phase 1 trial NCT07511205 is designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics in adults with overweight and/or obesity.